| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 14.3 | 14.2 | 12.5 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 14.3 | 14.2 | 12.6 |
| Profit before exceptional items & tax | 0.3 | 0.9 | 1.5 |
| Profit before tax | 0.3 | 0.3 | 1.5 |
| Net profit | 0.2 | -5.2 | 1.3 |
| Operating margin | 2.1% | 2.1% | 11.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -84.60% |
|---|---|
| Revenue, year on year | +14.40% |
BSE results filing, NSE: VIVOBIOT. Figures extracted from the filing.
Vivo Bio Tech Ltd: key numbers
- Share price
- ₹16.80
- Market cap
- ₹27.10 Cr
- Revenue (annual)
- ₹53.33 Cr
- Net profit (annual)
- ₹-1.71 Cr
- P/E (TTM)
- -9.5×Sector 50.4×
- Promoter holding
- 30.62%-4.81% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivo Bio Tech Ltd
All →Vivo Bio Tech Other Announcement
Vivo Bio Tech has sent letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26.
Vivo Bio Tech Annual Report
Vivo Bio Tech Limited has submitted its Annual Report for the financial year 2025-2026 along with the notice for its 39th Annual General Meeting.
Vivo Bio Tech Annual General Meeting
Vivo Bio Tech Ltd issued a notice for its 39th Annual General Meeting to be held on September 30, 2026, via video conferencing.
Vivo Bio Tech Q4 FY26 Results: Net Loss of ₹5.2 Cr
Vivo Bio Tech Ltd reported revenue from operations of ₹14.2 Cr (+15.4% YoY) and a net loss of ₹5.2 Cr for Q4 FY26.
- Key figure
- Net loss ₹5.2 Cr